BioCryst's peramivir priced and set for launch in Japan
This article was originally published in Scrip
Executive Summary
BioCryst Pharmaceuticals' intravenously infused antiviral, Rapiacta (peramivir), has received an expedited reimbursement price listing in Japan following its recent full regulatory approval in the country, the first worldwide.